ACT (2011) — Trial Summary
ACT (2011): The Acetylcysteine (ACT) trial evaluated whether oral acetylcysteine prevents contrast-induced acute kidney injury and associated adverse outcomes in high-risk patients undergoing coronary and peripheral angiography.
References
- ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250-1259.